BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Bristol-Myers Squibb Company (“Bristol-Myers” or the “Company”) (NYSE: BMY) investors concerning the Company and its officers’ possible violations of federal securities laws.
On August 5, 2016, the Company announced that its CheckMate -026 trial investigating the use of Opdivo as monotherapy did not meet its primary endpoint of progression-free survival.
On this news, the Company’s share price fell $12.04, or nearly 16%, to close at $63.28 per share on August 5, 2016, thereby injuring investors.
Then, on October 9, 2016, the Company further disclosed that in patients with ≥5% PD-L1 expression, the median progression-free survival was just 4.2 months with Opdivo compared to 5.9 months with platinum-based doublet chemotherapy.
On this news, the Company’s share price fell $5.62, or more than 10%, to close at $49.81 per share on October 10, 2016, thereby further injuring investors.
If you purchased Bristol-Myers securities between October 31, 2014 and October 9, 2016, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at 215-638-4847, toll-free at 888-638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.